News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
225,416 Results
Type
Article (5014)
Company Profile (17)
Press Release (220385)
Section
Business (82200)
Career Advice (462)
Deals (15042)
Drug Delivery (8)
Drug Development (19061)
Employer Resources (30)
FDA (3676)
Job Trends (3902)
News (120102)
Policy (7502)
Tag
Academia (292)
Accelerated approval (2)
Adcomms (3)
Allergies (9)
Alliances (14777)
ALS (20)
Alzheimer's disease (247)
Antibody-drug conjugate (ADC) (11)
Approvals (3695)
Artificial intelligence (43)
Autoimmune disease (3)
Automation (3)
Bankruptcy (97)
Best Places to Work (2862)
Biosimilars (11)
Biotechnology (21)
Bladder cancer (10)
Brain cancer (7)
Breast cancer (48)
Cancer (456)
Cardiovascular disease (24)
Career advice (394)
Career pathing (3)
CAR-T (33)
Cell therapy (107)
Cervical cancer (2)
Clinical research (16040)
Collaboration (172)
Compensation (172)
Complete response letters (2)
COVID-19 (301)
CRISPR (8)
C-suite (110)
Cystic fibrosis (16)
Data (526)
Depression (7)
Diabetes (43)
Diagnostics (2042)
Digital health (3)
Diversity, equity & inclusion (12)
Drug discovery (15)
Drug pricing (6)
Drug shortages (1)
Duchenne muscular dystrophy (11)
Earnings (40917)
Editorial (2)
Employer branding (6)
Employer resources (31)
Events (37837)
Executive appointments (315)
FDA (3941)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (2)
Funding (185)
Gene editing (16)
Generative AI (2)
Gene therapy (53)
GLP-1 (109)
Government (412)
Guidances (21)
Healthcare (5035)
Huntington's disease (1)
IgA nephropathy (4)
Immunology and inflammation (13)
Indications (6)
Infectious disease (317)
Inflammatory bowel disease (24)
Inflation Reduction Act (2)
Influenza (3)
Intellectual property (15)
Interviews (53)
IPO (7825)
IRA (3)
Job creations (1122)
Job search strategy (361)
Kidney cancer (7)
Labor market (5)
Layoffs (100)
Leadership (5)
Legal (2332)
Liver cancer (17)
Lung cancer (54)
Lymphoma (32)
Management (10)
Manufacturing (50)
MASH (29)
Medical device (3862)
Medtech (3863)
Mergers & acquisitions (7426)
Metabolic disorders (125)
Multiple sclerosis (8)
NASH (6)
Neurodegenerative disease (11)
Neuropsychiatric disorders (1)
Neuroscience (345)
NextGen: Class of 2025 (1675)
Non-profit (727)
Now hiring (3)
Obesity (53)
Opinion (30)
Ovarian cancer (17)
Pain (14)
Pancreatic cancer (14)
Parkinson's disease (28)
Partnered (4)
Patents (21)
Patient recruitment (33)
Peanut (5)
People (24608)
Pharmaceutical (5)
Pharmacy benefit managers (1)
Phase I (4783)
Phase II (6964)
Phase III (5551)
Pipeline (577)
Policy (9)
Postmarket research (625)
Preclinical (1873)
Press Release (66)
Prostate cancer (27)
Psychedelics (3)
Radiopharmaceuticals (105)
Rare diseases (70)
Real estate (1874)
Recruiting (8)
Regulatory (5126)
Reports (14)
Research institute (301)
Resumes & cover letters (68)
Rett syndrome (4)
Schizophrenia (21)
Series A (28)
Series B (23)
Sickle cell disease (7)
Special edition (1)
Spinal muscular atrophy (28)
Sponsored (4)
Startups (1009)
Stomach cancer (1)
Supply chain (10)
Tariffs (5)
Vaccines (37)
Venture capitalists (2)
Weight loss (22)
Women's health (1)
Date
Today (52)
Last 7 days (243)
Last 30 days (721)
Last 365 days (9886)
2025 (3235)
2024 (11028)
2023 (13193)
2022 (18659)
2021 (19678)
2020 (18238)
2019 (13205)
2018 (10205)
2017 (10002)
2016 (9156)
2015 (12118)
2014 (9587)
2013 (7707)
2012 (8329)
2011 (8796)
2010 (8634)
Location
Africa (185)
Alabama (13)
Alaska (2)
Arizona (59)
Arkansas (1)
Asia (11463)
Australia (1612)
California (1994)
Canada (718)
China (73)
Colorado (84)
Connecticut (97)
Delaware (30)
Europe (24546)
Florida (287)
Georgia (34)
Idaho (23)
Illinois (117)
India (7)
Indiana (64)
Iowa (2)
Japan (75)
Kansas (24)
Kentucky (11)
Louisiana (5)
Maine (40)
Maryland (226)
Massachusetts (1597)
Michigan (86)
Minnesota (141)
Mississippi (1)
Missouri (23)
Montana (16)
Nebraska (12)
Nevada (23)
New Hampshire (16)
New Jersey (577)
New Mexico (5)
New York (480)
North Carolina (332)
North Dakota (3)
Northern California (950)
Ohio (60)
Oklahoma (5)
Oregon (4)
Pennsylvania (353)
Puerto Rico (1)
Rhode Island (13)
South America (277)
South Carolina (6)
Southern California (719)
Tennessee (40)
Texas (230)
United States (7213)
Utah (61)
Virginia (47)
Washington D.C. (9)
Washington State (177)
West Virginia (2)
Wisconsin (25)
225,416 Results for "cyanotech corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Cyanotech Reports Financial Results for the First Quarter of Fiscal 2024
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2024, ended June 30, 2023.
August 11, 2023
·
6 min read
Business
Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2023
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2023, ended March 31, 2023.
June 27, 2023
·
7 min read
Business
Cyanotech Reports Financial Results for the First Quarter of Fiscal 2023
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the first quarter of fiscal year 2023, ended June 30, 2022.
August 10, 2022
·
6 min read
Business
Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2022
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results for the fourth quarter and fiscal year 2022, ended March 31, 2022.
June 22, 2022
·
8 min read
Business
Cyanotech Reports Financial Results for the First Quarter of Fiscal 2022
Cyanotech Corporation announced financial results for the first quarter of fiscal year 2022, ended June 30, 2021.
August 11, 2021
·
6 min read
Business
Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2021
Cyanotech Corporation announced financial results for the fourth quarter and fiscal year 2021, ended March 31, 2021.
June 22, 2021
·
7 min read
Cyanotech® Corporation Launches BioAstin®
Cyanotech® Corporation, (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health products, announces its launch of BioAstin® Hawaiian Astaxanthin® in a new delivery form, water dispersible powder, available in both 1% and 2% concentrations.
October 1, 2020
·
3 min read
Press Releases
Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing
Company executives will host a corporate webinar for investors and stakeholders on Thursday, April 10, 2025
March 31, 2025
·
12 min read
Press Releases
Quantum BioPharma Corporate Update
April 21, 2025
·
4 min read
Business
Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2021
Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and dietary supplements, announced financial results for the second quarter and first six months of fiscal year 2021, ended September 30, 2020. Cyanotech’s Chief Executive Officer, Gerald R. Cysewski, Ph.D., said: “Cyanotech continues to focus on its core operational functions. In packaged goods, we ar
November 12, 2020
·
7 min read
1 of 22,542
Next
